M. ABSCESSUS

M. abscessus: chronic lung disease with no approved drugs

Lung icon representing progressive, irreversible lung damage from persistent bacterial infection.

Progressive, irreversible lung damage
Persistent infection drives ongoing inflammation, declining lung function, and structural destruction

IV bag icon representing off-label intravenous treatment regimens.

No FDA-approved drugs
Off-label, 2 to 3 IV-only regimens with significant toxicities

Person icon representing the 20% five-year mortality rate and urgent patient need.

20% 5-year mortality
Creates urgency to treat individual patients and an imperative to develop efficacious and tolerable anti-bacterials

Illustration of lungs with a magnified view of air sacs damaged by M. abscessus infection.

A serious, difficult-to-treat, and chronic lung infection with a high mortality rate and no FDA-approved treatments

Current standard of care involves multi-drug regimens (inhaled and/or IV) given for ≥12 months after culture conversion. Treatment success rates are <50%, and there is significant toxicity risk from prolonged antibiotic exposure.

Epetraborole (EBO) has a novel mechanism of action in that it inhibits leucyl-tRNA synthetase (LeuRS; leucyl tRNA synthetase is an essential enzyme in protein synthesis). This mechanism has the potential to avoid existing resistance pathways seen with current therapies.

Preclinical highlights

Potent in vitro activity against M. abscessus clinical isolates, including macrolide-resistant strains.

Favorable pharmacokinetic properties supporting potential for oral dosing.

Low drug-to-drug interaction potential may be favorable in multi-drug regimens.

Bactericidal activity in preclinical pulmonary infection models.

Potent in vitro activity against M. abscessus clinical isolates, including macrolide-resistant strains.

Favorable pharmacokinetic properties supporting potential for oral dosing.

Low drug-to-drug interaction potential may be favorable in multi-drug regimens.

Bactericidal activity in preclinical pulmonary infection models.